Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PULM 
Pulmatrix Inc (PULM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: PULM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.7% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.90M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 1 | Beta 1.64 | 52 Weeks Range 1.96 - 10.40 | Updated Date 10/14/2025 |
52 Weeks Range 1.96 - 10.40 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.17 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2169.11% |
Management Effectiveness
Return on Assets (TTM) -45.62% | Return on Equity (TTM) -83.85% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8265627 | Price to Sales(TTM) 48.5 |
Enterprise Value 8265627 | Price to Sales(TTM) 48.5 | ||
Enterprise Value to Revenue 22.4 | Enterprise Value to EBITDA 1.57 | Shares Outstanding 3652285 | Shares Floating 3628107 |
Shares Outstanding 3652285 | Shares Floating 3628107 | ||
Percent Insiders 0.66 | Percent Institutions 9.34 |
Upturn AI SWOT
Pulmatrix Inc
Company Overview
History and Background
Pulmatrix, Inc. (PULM) is a biopharmaceutical company founded in 2003. It focuses on developing inhaled therapies to address pulmonary diseases. Milestones include developing the iSPERSE technology and advancing multiple drug candidates through preclinical and clinical stages.
Core Business Areas
- Inhaled Therapies Development: Develops inhaled therapies using its iSPERSE technology for respiratory diseases.
Leadership and Structure
Robert W. Clarke serves as Chief Executive Officer. The company has a typical organizational structure for a publicly traded biopharmaceutical company, with departments covering research, development, clinical operations, and finance.
Top Products and Market Share
Key Offerings
- PUR1900: A narrow-spectrum kinase inhibitor (nSKI) with anti-inflammatory properties. It is being developed for the treatment of severe asthma and potentially other lung diseases. There is no current market share. Competitors include big pharma players with inhaled corticosteroid and bronchodilator products and other companies developing novel asthma therapies.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the respiratory disease sector, is characterized by strong competition, regulatory hurdles, and high R&D costs.
Positioning
Pulmatrix is a small biopharmaceutical company attempting to innovate in the treatment of respiratory diseases, particularly asthma and COPD, through innovative inhaled drug technologies.
Total Addressable Market (TAM)
The global asthma and COPD market is estimated to be worth billions of dollars annually. Pulmatrix aims to capture a portion of this market with differentiated products if they receive regulatory approval.
Upturn SWOT Analysis
Strengths
- iSPERSE technology platform
- Experienced management team
- Pipeline of inhaled therapies
Weaknesses
- Limited financial resources
- Dependence on external funding
- No products currently on the market
- High risk of clinical trial failure
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expanding into new therapeutic areas
- Regulatory approval for PUR1900 or other candidates
Threats
- Competition from established pharmaceutical companies
- Failure of clinical trials
- Changes in regulatory landscape
- Economic downturn affecting funding
Competitors and Market Share
Key Competitors
- AZN
- GSK
- VRX
Competitive Landscape
Pulmatrix faces significant competition from large pharmaceutical companies with established respiratory products. Their iSPERSE technology gives them a potential edge.
Growth Trajectory and Initiatives
Historical Growth: Growth has been limited given the lack of marketed products. The stock price and valuation may fluctuate.
Future Projections: Future growth is highly dependent on the successful development and commercialization of drug candidates. Analyst projections vary greatly.
Recent Initiatives: Recent initiatives include advancing PUR1900 through clinical trials.
Summary
Pulmatrix is a high-risk, high-reward biopharmaceutical company focused on inhaled therapies. While their iSPERSE technology is promising, they face significant financial and clinical development hurdles. Their success hinges on the successful completion of clinical trials and potential partnerships. Investors should monitor their cash runway and clinical trial progress closely.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Investing in biopharmaceutical companies involves significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pulmatrix Inc
Exchange NASDAQ | Headquaters Framingham, MA, United States | ||
IPO Launch date 2014-03-21 | Interim CEO & Interim CFO Mr. Peter Ludlum CMA, MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://www.pulmatrix.com |
Full time employees 2 | Website https://www.pulmatrix.com | ||
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.